Pembrolizumab/Lenvatinib Extends Survival in Advanced/Recurrent Endometrial Cancer Subgroups
Christian Marth, MD, PhD, discusses outcomes for key subgroups treated with first-line pembrolizumab and lenvatinib in advanced or recurrent endometrial cancer.